PINEALON.INFO is a quiet, independent explainer about one very short peptide and the lab research around it. Nothing is sold on this site.
Pinealon
.INFO
The evidence

What the studies say

Before you read on: Almost all Pinealon research comes from one network of laboratories in St Petersburg. Most of it was done in cell cultures, rodents or computer models. No randomised clinical trial has been published.

A search of PubMed, the main index of medical research, turns up only a few dozen papers that mention Pinealon or its EDR sequence. Many are short reports or reviews by the same authors. Below we sort the most relevant ones by type, so it is clear what kind of evidence each piece is.

Who did the research

The St Petersburg Institute of Bioregulation and Gerontology and partner groups in the same city are named on nearly every paper. That is not wrong in itself, since every field starts somewhere, but it means the results have rarely been checked by independent teams. Several studies were also published in Russian only, with limited detail available to outside readers.

Studies in cells

  • Less oxidative stress (Rejuvenation Res, 2011): in rat brain cells, immune cells and a nerve-like cell line, Pinealon lowered harmful oxygen by-products and reduced cell death.
  • Getting into the nucleus (Biochemistry (Mosc), 2011): fluorescently tagged short peptides, Pinealon among them, were seen inside human cells and their nuclei.
  • Serotonin-related genes (Bull Exp Biol Med, 2014): in ageing cultures of cortex cells, the peptide increased markers of serotonin production.
  • Neuron spines (Bull Exp Biol Med, 2017): in mouse hippocampal neurons exposed to an Alzheimer's-type toxic protein, it brought the number of mushroom spines back to normal.
  • Neurons from older donors (Int J Mol Sci, 2024): in nerve cells grown from elderly people's skin cells, it increased dendrite branching and reduced one kind of DNA damage, but left several other ageing markers unchanged.

Studies in animals

  • Rat offspring (Int J Clin Exp Med, 2012): offspring of pregnant rats given Pinealon during a diet-induced imbalance showed better spatial learning and hardier cerebellum cells.
  • Older rats under stress (Adv Gerontol, 2015): a Russian-language study compared Pinealon with another peptide product in rats exposed to low oxygen or mild cold; the other product had the stronger effect on several brain markers.
  • Alzheimer's model mice (Pharmaceuticals, 2021): work in mice bred to develop Alzheimer-like changes, together with computer modelling, suggested the peptide protected dendritic spines; much of the paper is theoretical.

Chemistry and computer models

  • Binding to DNA (J Phys Chem B, 2019): physicists measured how the EDR peptide can sit in a groove of the DNA double helix, helped by magnesium.
  • Getting into cells (Biomolecules, 2023): docking simulations suggested short peptides like EDR could be carried into cells by known transporter proteins.
  • Review by the originating group (Molecules, 2020): a summary of the proposed gene-regulation mechanism in Alzheimer's disease, written by the same researchers.

Studies in people

Human data are very thin. A 2012 Russian-language report described professional truck drivers given bioregulator peptides, with the best results said to come from combining Pinealon with another product. The published summary gives little detail on randomisation or blinding, and the claims have not been repeated in a registered trial. A search of ClinicalTrials.gov lists no study of Pinealon at all.

How to read these findings

Cell and animal results are a starting point, not proof. Many substances protect nerve cells in a dish and then fail in people, for example because they never reach the brain or because the doses that work in rodents do not translate. Without independent replication and controlled human trials, it is impossible to say whether Pinealon does anything useful for human health.

What is missing

  • Independent replication: results from laboratories with no link to the originating group.
  • Human trials: randomised, placebo-controlled and registered in advance.
  • Basic pharmacology: how long the peptide survives in the body and whether it reaches the brain.
  • Safety data: systematic tracking of side effects over time.

Bottom line

Pinealon has an interesting set of early lab findings around nerve cells and stress. The evidence is narrow, mostly preclinical and largely from one source, so it should be treated as a hypothesis worth testing rather than an established fact.

References

  1. Fedoreyeva LI, Kireev II, Khavinson VKh, Vanyushin BF. Penetration of short fluorescence-labeled peptides into the nucleus in HeLa cells and in vitro specific interaction of the peptides with deoxyribooligonucleotides and DNA. Biochemistry (Mosc). 2011;76(11):1210-1219. PMID 22117547
  2. Khavinson V, Ribakova Y, Kulebiakin K, et al. Pinealon increases cell viability by suppression of free radical levels and activating proliferative processes. Rejuvenation Res. 2011;14(5):535-541. PMID 21978084
  3. Arutjunyan A, Kozina L, Stvolinskiy S, et al. Pinealon protects the rat offspring from prenatal hyperhomocysteinemia. Int J Clin Exp Med. 2012;5(2):179-185. PMID 22567179
  4. Bashkireva AS, Artamonova VG. The peptide correction of neurotic disorders among professional truck-drivers [in Russian]. Adv Gerontol. 2012;25(4):718-728. PMID 23734521
  5. Khavinson VKh, Lin'kova NS, Tarnovskaya SI, et al. Short peptides stimulate serotonin expression in cells of brain cortex. Bull Exp Biol Med. 2014;157(1):77-80. PMID 24909721
  6. Mendzheritsky AM, Karantysh GV, Ryzhak GA, Prokofiev VN. Pinealon and Cortexin influence on behavior and neurochemical processes in 18-month aged rats within hypoxia and hypothermia [in Russian]. Adv Gerontol. 2015;28(3):532-539. PMID 28509493
  7. Kraskovskaya NA, Kukanova EO, Lin'kova NS, Popugaeva EA, Khavinson VK. Tripeptides restore the number of neuronal spines under conditions of in vitro modeled Alzheimer's disease. Bull Exp Biol Med. 2017;163(4):550-553. PMID 28853087
  8. Silanteva IA, Komolkin AV, Morozova EA, et al. Role of mono- and divalent ions in peptide Glu-Asp-Arg-DNA interaction. J Phys Chem B. 2019;123(9):1896-1902. PMID 30762356
  9. Khavinson V, Linkova N, Kozhevnikova E, Trofimova S. EDR peptide: possible mechanism of gene expression and protein synthesis regulation involved in the pathogenesis of Alzheimer's disease. Molecules. 2020;26(1):159. PMID 33396470
  10. Khavinson V, Ilina A, Kraskovskaya N, et al. Neuroprotective effects of tripeptides-epigenetic regulators in mouse model of Alzheimer's disease. Pharmaceuticals (Basel). 2021;14(6):515. PMID 34071923
  11. Khavinson VK, Linkova NS, Rudskoy AI, Petukhov MG. Feasibility of transport of 26 biologically active ultrashort peptides via LAT and PEPT family transporters. Biomolecules. 2023;13(3):552. PMID 36979488
  12. Kraskovskaya N, Linkova N, Sakhenberg E, et al. Short peptides protect fibroblast-derived induced neurons from age-related changes. Int J Mol Sci. 2024;25(21):11363. PMID 39518916